Table 3.
Medication Adherence, Detectable Buprenorphine Blood Level, Behavioral Treatment Compliance, and Retention by Treatment Arm*
| PLB (N=102) | BUP4 (N=100) | BUP16 (N=100) | |
|---|---|---|---|
| Medication Adherence** | |||
| Mean Number of 2mg pills reported taken (SD) | 87.5 (31.81) | 83.5 (34.04) | 82.3 (32.58) |
| Mean Number of 8mg pills reported taken (SD) | 87.5 (31.81) | 83.5 (34.04) | 82.3 (32.58) |
| Mean Proportion Sublingual Medication Adherence (SD) | 91.3 (13.07) | 91.9 (11.17) | 87.4 (16.43) |
| Percentage Received XR-NTX Injection #2 | 89 (87.3%) | 86 (86.0%) | 88 (88.0%) |
| Detectable Buprenorphine Blood Level | |||
| Week 5 Buprenorphine Blood Level | 1/86 (1.2%) | 61/82 (74.4%) | 63/85 (74.1%) |
| Week 5 Norbuprenorphine Blood Level | 2/86 (2.3%) | 67/82 (81.7%) | 66/85 (77.7%) |
| Week 5 Buprenorphine/Norbuprenorphine Blood Level | 2/86 (2.3%) | 68/82 (82.9%) | 67/85 (78.8%) |
| Week 8 Buprenorphine Blood Level | 0/74 (0.0%) | 34/67 (50.8%) | 44/66 (66.7%) |
| Week 8 Norbuprenorphine Blood Level | 1/74 (1.3%) | 43/67 (64.2%) | 45/66 (68.2%) |
| Week 8 Buprenorphine/Norbuprenorphine Blood Level | 1/74 (1.3%) | 46/67 (68.7%) | 47/66 (71.2%) |
| Behavioral Treatment Compliance | |||
| Number of CBT Sessions Attended/Expected | 672/816 | 655/800 | 653/800 |
| Percent Expected CBT Sessions Attended | 82.4% | 81.9% | 81.6% |
| Mean CBT*** Sessions Attended per Participant (SD) | 6.6 (2.03) | 6.6 (2.17) | 6.5 (2.14) |
| Retention | |||
| Participants who provided self-report data during evaluation period (Weeks 5–8) | 100 (98%) | 95 (95%) | 97 (97%) |
| Mean Days to Last Dose (SD) | 48.9 (16.0) | 47.2 (17.7) | 48.4 (16.1) |
| Early Medication Terminations | 15.7% | 21.0% | 17.0% |
| Mean # Missed Visits per Participant | 3.2 | 3.5 | 3.7 |
| Attendance Weeks 1–4 | 89.6% | 87.4% | 86.9% |
| Attendance Weeks 5–8 | 84.9% | 81.8% | 82.0% |
| Attendance Month 1 follow-up visit | 95.1% | 91.0% | 93.0% |
| Attendance Month 3 follow-up visit | 91.2% | 87.0% | 91.0% |
*
No statistically significant difference for any variable presented in Table 3;
**
no significant difference in buprenorphine blood level between the two groups who received buprenorphine.
***
CBT=Cognitive Behavioral Therapy